- Home
- BDRX vs VBIO Comparison
BDRX vs VBIO Comparison
Compare BDRX & VBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDRX | VBIO |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6M | 1.6M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BDRX | VBIO |
|---|---|---|
| Price | $1.27 | $0.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 46.0K | ★ 17.6M |
| Earning Date | 09-12-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $780,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.60 | $0.11 |
| 52 Week High | $11.88 | $1.30 |
Technical Indicators
Market Signals| Indicator | BDRX | VBIO |
|---|---|---|
| Relative Strength Index (RSI) | 29.78 | 24.00 |
| Support Level | $1.03 | N/A |
| Resistance Level | $1.50 | $0.44 |
| Average True Range (ATR) | 0.19 | 0.13 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 19.23 | 0.78 |
Price Performance
Historical ComparisonAbout BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About VBIO Valion Bio Inc. Common Stock
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.